According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...

SAN DIEGO--(BUSINESS WIRE)--Inocras, a leader in whole genome sequencing (WGS) and bioinformatics, has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

In this exclusive MedPage Today video, Nicholas Short, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses the results with ponatinib (Iclusig) and blinatumomab (Blincyto) ...

Minimal residual disease (MRD) can predict which patients with classical Hodgkin lymphoma (HL) will relapse after autologous stem cell transplantation (ASCT). Minimal residual disease (MRD) could be ...

The first and only test authorized by the FDA to detect and monitor minimal residual disease (MRD) in multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) has received coverage for ...

MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of ...

"Cancer liquid biopsy has the potential to revolutionize cancer diagnosis, treatment monitoring, and the detection of minimal residual disease (MRD) soon after therapy—helping to better personalize ...

Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...